Joint inflammation in hemophilia A patients
Part of Blood & lymphatic, Bones, joints & muscles, Genetic & congenital clinical trials.
This study looks at how many adults with moderate or severe hemophilia A have inflammation in their joints (synovitis). It aims to better understand joint health in people with hemophilia A, including those with inhibitors or joint replacements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have moderate or severe hemophilia A (even if you have an inhibitor or a joint replacement)
- Your medical records include details about your hemophilia, treatments over the past year, and any bleeds in the past year
- You are not currently taking part in a study testing an investigational drug
- You do not have another bleeding disorder that could interfere with this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the cells and molecules in the joint tissue of people with arthritis. The goal is to better understand arthritis and potentially improve treatments.
This study looks at whether a “blocking” procedure (embolization) can improve long-lasting joint inflammation caused by inherited bleeding disorders. It focuses on people with joint lining inflammation from repeated bleeding into the joint.
This study uses ultrasound to check if thickened joint lining (synovium) in people with severe hemophilia is a sign of active inflammation or just a harmless leftover. It may help doctors decide whether to treat or watch these joints.
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
This study uses ultrasound to check if joints that are currently healthy stay healthy in people with hemophilia A who are taking emicizumab (Hemlibra) as their regular treatment. It aims to see if this treatment helps prevent joint damage over time.
This study uses ultrasound to check the health of your joints. It aims to see if people with mild hemophilia have joint problems even without frequent bleeding, which could help guide future treatment.
Hear when a new Synovitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.